Dr. Edward Goodwin is an insightful scientist, investor, and entrepreneur fusing a Ph.D. in Molecular Biology and Microbiology with hands-on experience in evaluating, funding, and guiding growing companies and startups. Over three decades of basic scientific research, Dr. Goodwin has demonstrated a fearless adoption and mastery of novel techniques addressing important scientific questions. He is a proven, dynamic operations professional skilled in management, Molecular & Cellular Biology, Virology, and Research and Development (R&D). Beyond his scientific achievements, Dr. Goodwin is an activist board member and angel investor, contributing his knowledge and experience to the advancement of the biotech and startup ecosystems.

Dr. Goodwin’s involvement with NeuroEM Therapeutics began in 2016 as an early investor and advisor, and he was elected as a Board Member in 2019. Today, he serves as the Principal Investigator for an SBIR phase II grant and provides ongoing scientific leadership to the NeuroEM team as the Chief Scientist. He has served as Director and Past President of the Angel Investor Forum, where he has been involved in member engagement, startup outreach, and entrepreneur mentoring since 2009.

Dr. Goodwin served a nearly 20-year-long tenure as a Postdoctoral Fellow and then Faculty member at the Department of Genetics, Yale University School of Medicine, where he made significant discoveries in viral infection mechanisms, tumor formation, and cellular aging. Following his time at Yale, Dr. Goodwin spearheaded clinical trial designs, optimized precision medicine tests, and established a CLIA lab at Bioarry Genetics; fostered strategic alliances for Connecticut's bioscience community at CURE; and guided technical strategy and funding for a startup at TBP Pharma. He holds a Ph.D. in Molecular Biology and Microbiology from Case Western Reserve University and a bachelor’s degree in biology and chemistry from Oberlin College.

LinkedIn Profile